<DOC>
	<DOCNO>NCT00958815</DOCNO>
	<brief_summary>People diabetes increase risk atherosclerosis high CVD morbidity mortality rate . Tools detect quantify atherosclerotic pro/regression people diabetes CVD risk factor lack sensitivity specificity molecular level event occur early stage atherogenesis . Inflammatory macrophage infiltration vessel endothelium early , molecular level proatherogenic event . Activated macrophage consume glucose high rate . Novel vivo radiotracer PET/CT technique develop detect , image quantify molecular level event like macrophage inflammation glucose utilization ( 18FDG ) human vessel . We propose develop test novel technique Center Clinical Imaging Research ( CCIR ) WUMS . We propose HIV-infected people significant CVD risk profile suitable , unique human model test novel image technique . HIV-infected people take anti-HIV medication develop insulin resistance , T2DM , dyslipidemia , central adiposity , hypertension . HIV replicate macrophage represent chronic proinflammatory condition . Recent data indicate HIV+ CVD risk great risk atherosclerosis MI HIV-negative people . To test feasibility , hypothesize : a.18FDG-PET/CT imaging detect macrophage glucose uptake inflammation carotid aorta arteries HIV-infected people CVD risk HIV-negative control ; b. radiotracer PET/CT measure proatherogenic process correlate carotid intima medium thickness ; standard measure carotid atherosclerotic burden . We propose obtain pilot data show feasibility novel analytical approach expand capabilities researcher interested study link diabetes , inflammation , CVD human .</brief_summary>
	<brief_title>Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Plaque , Atherosclerotic</mesh_term>
	<criteria>Inclusion Criteria HIV+ group : confirm HIV+ status 3560 year old stable ART least past 4 mo CD4 count &gt; 200 cells/ÂµL HIV RNA &lt; 40copies/mL fast glucose=100126 mg/dL 2hroGTT glucose=140200mg/dL fast triglyceride &gt; 150mg/dL HDLcholesterol &lt; 40mg/dL ( men ) , &lt; 50mg/dL ( woman ) rest blood pressure &gt; 130/85mmHg waist circumference &gt; 102cm ( men ) , &gt; 88cm ( woman ) BMI 2535 kg/m2 For HIVnegative control group : Confirmed HIV negative status 3560 year old fasting glucose &lt; 100mg/dL , 2hroGTT glucose &lt; 140mg/dL fast triglyceride &lt; 150mg/dL HDLcholesterol &gt; 40mg/dL ( men ) , &gt; 50mg/dL ( woman ) normal BP ( &lt; 130/85mmHg ) central adiposity ( waist circ. &lt; 102cm ( men ) , &lt; 88cm ( woman ) BMI ( 2535 kg/m2 ) Exclusion Criteria group : history heart disease , MI , stroke , transient ischemic attack , kidney liver disease ( active hepatitis B C ) , dementia statin , fibrates , TZDs , antihypertensives , low dose aspirin , prescribed/overthecounter agent antiinflammatory property cocaine methamphetamine user serum creatinine &gt; 1.5 mg/dL pregnant woman cognitive impairment limit ability provide voluntary informed consent</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>vascular imaging</keyword>
	<keyword>diabetes</keyword>
	<keyword>rupture prone plaque</keyword>
	<keyword>HIV</keyword>
	<keyword>treatment experience</keyword>
</DOC>